Developer docs
API playgroundTry for free, no card

Search company profiles

IMIDomics

Full company profile

uuid0002k3r

Namestring
IMIDomics
Legal namestring
IMIDomics, Inc.
Websiteurl
imidomics.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

IMIDomics is a clinical-stage biotechnology company founded in 2015 as a spin-off from the Vall d'Hebron University Hospital and the IMID Consortium initiated by Dr. Sara Marsal in 2006. The company is focused on discovering and developing first-in-class therapeutics for immune-mediated inflammatory diseases (IMIDs), targeting eight indications: Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, and Sjögren's Syndrome. Its core asset is a proprietary Clinical Discovery Engine (also referred to as the Precision Discovery Platform) that combines 17+ years of patient data from a network of 130+ recruiting centers and 300+ investigators across Spain (with extension to Paraguay), an ISO-certified IMID-Biobank with >17,000 patient samples and >1M biological specimens, >10,000 clinical variables, and 2M+ data points, processed through multi-omics analyses and bioinformatics to identify novel drug targets and biomarkers for patient stratification. The lead pipeline asset, IMB1001, is a first-in-class anti-CD226 antibody modulating innate and adaptive immunity.

The company monetizes through a licensing and partnership model rather than direct commercialization. Revenue streams consist of research collaborations and professional services engagements with pharmaceutical partners, supplemented by potential milestone payments and royalties from out-licensed drug candidates. Strategic partners and investors include Bristol Myers Squibb, Evotec SE, UCB (which made a strategic equity investment in March 2024 and completed a full acquisition in June 2026), WuXi Biologics, Twist Bioscience, Formation Bio (which licensed the anti-CD226 program in July 2025), and TNAX Biopharma (original IMB1001 licensor). Go-to-market is enterprise-oriented, targeting large pharmaceutical companies for co-development, licensing, and commercialization of IMID therapeutics, with academic medical centers serving as secondary collaborators. As of June 2026, IMIDomics operates as a subsidiary of UCB following acquisition, with headquarters in San Rafael, California and a permanent European establishment in Barcelona, Spain, employing 11-50 staff.

Short descriptiontext

IMIDomics is a biotechnology company developing first-in-class therapeutics for immune-mediated inflammatory diseases using a proprietary Clinical Discovery Engine built on 17+ years of multi-omics patient data and an ISO-certified biobank of over 17,000 IMID patients, monetizing through licensing and research collaborations with pharmaceutical partners.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Rafael, United States
HQ citystring
San Rafael
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, inflammatory disease therapeutics, multi-omics biomarker analysis, clinical biobank services, biopharmaceutical pipeline development
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Licensing
TypeLicensing Royalties
Description

IMIDomics develops novel therapeutics for IMIDs and partners with pharmaceutical companies for co-development, licensing, and commercialization. Revenue is generated through strategic partnerships, licensing agreements, and potential milestone payments.

biospace.com
2Research Collaborations
TypeProfessional Services
Description

Collaborations with pharmaceutical companies for target discovery, biomarker identification, and clinical development support, generating revenue through research funding and development milestones.

imidomics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, lupus, ulcerative colitis, psoriasis, Crohn's disease, and atopic dermatitis. Its proprietary Clinical Discovery Engine combines patient-centric clinical data from over 17,000 IMID patients, multi-omics analyses, and bioinformatics to identify novel drug targets and patient stratification biomarkers. The company partners with pharmaceutical companies (UCB, Bristol Myers Squibb, Evotec) for co-development, licensing, and commercialization of its therapeutic pipeline, including the lead program IMB1001 (anti-CD226 antibody).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 4 of 5 Ulcerative Colitis patients fail to achieve remission with current treatments
+2 more records
Product overview1 text field

IMIDomics is a biotechnology company developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs). The company operates a unified Clinical Discovery Engine platform that combines proprietary patient data, multi-omics analysis, and bioinformatics to discover and develop first-in-class therapeutic targets. The platform integrates an IMID-Biobank with over 17,000 patient samples and clinical data from 130 recruiting centers. IMIDomics' pipeline includes multiple first-in-class programs, with IMB1001 (anti-CD226 antibody) being the most advanced drug candidate that has been out-licensed for further development.

Product and service4 records
1Clinical Discovery Engine
CategoryDrug Discovery Platform
Description

Proprietary platform combining patient data collection, multi-omics generation (genomics, transcriptomics, epigenetics, proteomics, metabolomics), bioinformatics analysis, and AI/ML for target identification, biomarker discovery, and patient stratification in immune-mediated inflammatory diseases. Offered to pharmaceutical partners for drug discovery and development.

2Precision Discovery Platform
CategoryDrug Discovery Platform
Description

AI- and machine learning-enhanced version of IMIDomics' drug discovery platform that leverages comprehensive IMID patient data and biobank resources to identify and develop first-in-class therapeutic targets.

3IMB1001 (Anti-CD226 Antibody)
CategoryTherapeutic Candidate
Description

First-in-class antibody program targeting CD226 signaling that modulates both innate and adaptive immunity. Licensed from TNAX Biopharma (as TNAX101A) and being developed for immune-mediated inflammatory diseases by WuXi Biologics (CMC/manufacturing) and Formation Bio (development rights).

4IMID-Biobank
CategoryBiorepository / Data Service
Description

ISO-certified biorepository containing over 1 million biological specimens (blood and relevant tissues) from over 17,000 IMID patients and control subjects across eight IMIDs, with cross-sectional and longitudinal data collection. Supports multi-omics research and pharmaceutical partner access.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-07-29
Description

Formation Bio licensed the first-in-class anti-CD226 autoimmune program from IMIDomics. This represents the first drug licensed by Formation since their $372M raise.

2University of Barcelona
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-11
Description

License and collaboration partnership established in October 2023 to advance treatments for IMIDs. The University of Barcelona contributes academic research expertise to the collaboration.

imidomics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-04
Description

Strategic agreement announced in October 2023 to advance IMB1001 antibody development for immune-mediated inflammatory diseases. WuXi Biologics provides CMC development and manufacturing capabilities.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-09-06
Description

Exclusive worldwide licensing agreement for TNAX101A (IMB1001), a promising drug candidate for IMIDs. TNAX provides access to the compound that became IMB1001.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-02-02
Description

Strategic collaboration to advance the development of novel treatments for patients with immune-mediated inflammatory diseases, established in February 2020.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

VHIR is a key academic partner providing patient data and sample collection infrastructure. The IMID-Biobank is located at VHIR and samples are stored there. The partnership dates back to the company's origins from the IMID Consortium started by Dr. Sara Marsal.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DoCTIS is an EU-funded Horizon 2020 project focused on discovering effective combinatorial therapies for IMIDs using systems approaches. Dr. Sara Marsal serves as coordinator. IMIDomics participates in this broad academic partnership to explore combination therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Prometheus Biosciences (acquired by Merck)
TypeDirect peer
Description

Precision-medicine biotech focused on immune-mediated diseases (IBD, IBD-related) using proprietary patient data and biomarker discovery; very similar discovery-plus-stratification model in the IMID space and the most directly comparable peer.

2Morphic Holding (acquired by Eli Lilly)
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin therapeutics for IMIDs including IBD; shares the immunology/inflammation focus and partnership-driven development model with IMIDomics.

TypeDirect peer
Description

AI-powered antibody discovery platform partnering with pharma to identify therapeutic candidates; directly comparable as a technology-driven, partnership-monetized antibody/biologic discovery company.

4Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharma with established IMID franchises (Zeposia, Sotyktu, deucravacitinib) and a Series A investor and ongoing collaborator of IMIDomics; competes broadly in the same therapeutic indications.

TypeBroad incumbent
Description

Global immunology leader with Humira, Skyrizi, and Rinvoq dominating IMID markets; sets the competitive bar for any new IMID therapeutic including IMIDomics' pipeline.

TypeBroad incumbent
Description

Specialist biopharma with major IMID franchise (Cimzia, evenity, Rystiggo/Zilbrysq); strategic equity investor in and ultimate acquirer of IMIDomics, providing commercial reach for IMIDomics' pipeline.

TypeBroad incumbent
Description

Major immunology player (Taltz, Olumiant, mirikizumab) actively expanding in IBD and atopic dermatitis; competes for the same indications IMIDomics targets.

TypeEmerging player
Description

AI-driven drug discovery platform using large-scale biological and chemical data to identify novel targets; comparable as a tech-enabled discovery company, though with a broader therapeutic focus than IMIDomics.

TypeEmerging player
Description

AI-first pharma using precision medicine and computational drug design; shares the AI/ML-enabled discovery and pharma partnership business model with IMIDomics.

TypeEmerging player
Description

Clinical-stage immunology biotech developing therapeutics for IMIDs (IBD, pulmonary); established strategic collaborator with IMIDomics (2020) addressing overlapping indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IMIDomics

Biopharmaceutical Drug Discoveryimidomics.com

IMIDomics is a biotechnology company developing first-in-class therapeutics for immune-mediated inflammatory diseases using a proprietary Clinical Discovery Engine built on 17+ years of multi-omics patient data and an ISO-certified biobank of over 17,000 IMID patients, monetizing through licensing and research collaborations with pharmaceutical partners.

What IMIDomics does

IMIDomics is a clinical-stage biotechnology company founded in 2015 as a spin-off from the Vall d'Hebron University Hospital and the IMID Consortium initiated by Dr. Sara Marsal in 2006. The company is focused on discovering and developing first-in-class therapeutics for immune-mediated inflammatory diseases (IMIDs), targeting eight indications: Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, and Sjögren's Syndrome. Its core asset is a proprietary Clinical Discovery Engine (also referred to as the Precision Discovery Platform) that combines 17+ years of patient data from a network of 130+ recruiting centers and 300+ investigators across Spain (with extension to Paraguay), an ISO-certified IMID-Biobank with >17,000 patient samples and >1M biological specimens, >10,000 clinical variables, and 2M+ data points, processed through multi-omics analyses and bioinformatics to identify novel drug targets and biomarkers for patient stratification. The lead pipeline asset, IMB1001, is a first-in-class anti-CD226 antibody modulating innate and adaptive immunity.

The company monetizes through a licensing and partnership model rather than direct commercialization. Revenue streams consist of research collaborations and professional services engagements with pharmaceutical partners, supplemented by potential milestone payments and royalties from out-licensed drug candidates. Strategic partners and investors include Bristol Myers Squibb, Evotec SE, UCB (which made a strategic equity investment in March 2024 and completed a full acquisition in June 2026), WuXi Biologics, Twist Bioscience, Formation Bio (which licensed the anti-CD226 program in July 2025), and TNAX Biopharma (original IMB1001 licensor). Go-to-market is enterprise-oriented, targeting large pharmaceutical companies for co-development, licensing, and commercialization of IMID therapeutics, with academic medical centers serving as secondary collaborators. As of June 2026, IMIDomics operates as a subsidiary of UCB following acquisition, with headquarters in San Rafael, California and a permanent European establishment in Barcelona, Spain, employing 11-50 staff.

IMIDomics firmographics

Firmographics
Name
IMIDomics
Legal name
IMIDomics, Inc.
Website
https://imidomics.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
IMIDomics is a biotechnology company developing first-in-class therapeutics for immune-mediated inflammatory diseases using a proprietary Clinical Discovery Engine built on 17+ years of multi-omics patient data and an ISO-certified biobank of over 17,000 IMID patients, monetizing through licensing and research collaborations with pharmaceutical partners.
Ownership category
akta.pro rank

IMIDomics industry classification

Industry
Product category
Biopharmaceutical Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Drug discovery platform
  • Inflammatory disease therapeutics
  • Multi-omics biomarker analysis
  • Clinical biobank services
  • Biopharmaceutical pipeline development

Where IMIDomics is headquartered

Location

Headquarters

HQ city
San Rafael
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IMIDomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Licensing: IMIDomics develops novel therapeutics for IMIDs and partners with pharmaceutical companies for co-development, licensing, and commercialization. Revenue is generated through strategic partnerships, licensing agreements, and potential milestone payments.
  2. Research Collaborations: Collaborations with pharmaceutical companies for target discovery, biomarker identification, and clinical development support, generating revenue through research funding and development milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

IMIDomics product offering

Product offering

Core offering

IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, lupus, ulcerative colitis, psoriasis, Crohn's disease, and atopic dermatitis. Its proprietary Clinical Discovery Engine combines patient-centric clinical data from over 17,000 IMID patients, multi-omics analyses, and bioinformatics to identify novel drug targets and patient stratification biomarkers. The company partners with pharmaceutical companies (UCB, Bristol Myers Squibb, Evotec) for co-development, licensing, and commercialization of its therapeutic pipeline, including the lead program IMB1001 (anti-CD226 antibody).

Product overview

IMIDomics is a biotechnology company developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs). The company operates a unified Clinical Discovery Engine platform that combines proprietary patient data, multi-omics analysis, and bioinformatics to discover and develop first-in-class therapeutic targets. The platform integrates an IMID-Biobank with over 17,000 patient samples and clinical data from 130 recruiting centers. IMIDomics' pipeline includes multiple first-in-class programs, with IMB1001 (anti-CD226 antibody) being the most advanced drug candidate that has been out-licensed for further development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Discovery Engine Proprietary platform combining patient data collection, multi-omics generation (genomics, transcriptomics, epigenetics, proteomics, metabolomics), bioinformatics analysis, and AI/ML for target identification, biomarker discovery, and patient stratification in immune-mediated inflammatory diseases. Offered to pharmaceutical partners for drug discovery and development.
  • Precision Discovery Platform AI- and machine learning-enhanced version of IMIDomics' drug discovery platform that leverages comprehensive IMID patient data and biobank resources to identify and develop first-in-class therapeutic targets.
  • IMB1001 (Anti-CD226 Antibody) First-in-class antibody program targeting CD226 signaling that modulates both innate and adaptive immunity. Licensed from TNAX Biopharma (as TNAX101A) and being developed for immune-mediated inflammatory diseases by WuXi Biologics (CMC/manufacturing) and Formation Bio (development rights).
  • IMID-Biobank ISO-certified biorepository containing over 1 million biological specimens (blood and relevant tissues) from over 17,000 IMID patients and control subjects across eight IMIDs, with cross-sectional and longitudinal data collection. Supports multi-omics research and pharmaceutical partner access.

Quantifiable outcome

  • 4 of 5 Ulcerative Colitis patients fail to achieve remission with current treatments
  • +2 more outcomes

Companies that use IMIDomics

Customer profile

Segments3 records

Ideal customer profiles2 records

IMIDomics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

IMIDomics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Formation BiocoreOEM/ Whitelabel/ Licensing Partner · 29 July 2025Formation Bio licensed the first-in-class anti-CD226 autoimmune program from IMIDomics. This represents the first drug licensed by Formation since their $372M raise.
  • University of BarcelonaminorStrategic or Co-development Partner · 11 October 2023License and collaboration partnership established in October 2023 to advance treatments for IMIDs. The University of Barcelona contributes academic research expertise to the collaboration.
  • WuXi BiologicscoreStrategic or Co-development Partner · 4 October 2023Strategic agreement announced in October 2023 to advance IMB1001 antibody development for immune-mediated inflammatory diseases. WuXi Biologics provides CMC development and manufacturing capabilities.
  • TNAX Biopharma CorporationcoreOEM/ Whitelabel/ Licensing Partner · 6 September 2023Exclusive worldwide licensing agreement for TNAX101A (IMB1001), a promising drug candidate for IMIDs. TNAX provides access to the compound that became IMB1001.
  • Gossamer BiominorStrategic or Co-development Partner · 2 February 2020Strategic collaboration to advance the development of novel treatments for patients with immune-mediated inflammatory diseases, established in February 2020.
  • Vall d'Hebron Institute of Research (VHIR)coreStrategic or Co-development PartnerVHIR is a key academic partner providing patient data and sample collection infrastructure. The IMID-Biobank is located at VHIR and samples are stored there. The partnership dates back to the company's origins from the IMID Consortium started by Dr. Sara Marsal.
  • DocTIScoreStrategic or Co-development PartnerDoCTIS is an EU-funded Horizon 2020 project focused on discovering effective combinatorial therapies for IMIDs using systems approaches. Dr. Sara Marsal serves as coordinator. IMIDomics participates in this broad academic partnership to explore combination therapies.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

IMIDomics competitors and assessment

Company assessment

Direct peers

  • Prometheus Biosciences (acquired by Merck): Precision-medicine biotech focused on immune-mediated diseases (IBD, IBD-related) using proprietary patient data and biomarker discovery; very similar discovery-plus-stratification model in the IMID space and the most directly comparable peer.
  • Morphic Holding (acquired by Eli Lilly): Clinical-stage biotech developing oral integrin therapeutics for IMIDs including IBD; shares the immunology/inflammation focus and partnership-driven development model with IMIDomics.
  • AbCellera Biologics: AI-powered antibody discovery platform partnering with pharma to identify therapeutic candidates; directly comparable as a technology-driven, partnership-monetized antibody/biologic discovery company.

Broad incumbents

  • Bristol Myers Squibb: Large pharma with established IMID franchises (Zeposia, Sotyktu, deucravacitinib) and a Series A investor and ongoing collaborator of IMIDomics; competes broadly in the same therapeutic indications.
  • AbbVie: Global immunology leader with Humira, Skyrizi, and Rinvoq dominating IMID markets; sets the competitive bar for any new IMID therapeutic including IMIDomics' pipeline.
  • UCB: Specialist biopharma with major IMID franchise (Cimzia, evenity, Rystiggo/Zilbrysq); strategic equity investor in and ultimate acquirer of IMIDomics, providing commercial reach for IMIDomics' pipeline.
  • Eli Lilly: Major immunology player (Taltz, Olumiant, mirikizumab) actively expanding in IBD and atopic dermatitis; competes for the same indications IMIDomics targets.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery platform using large-scale biological and chemical data to identify novel targets; comparable as a tech-enabled discovery company, though with a broader therapeutic focus than IMIDomics.
  • Exscientia: AI-first pharma using precision medicine and computational drug design; shares the AI/ML-enabled discovery and pharma partnership business model with IMIDomics.
  • Gossamer Bio: Clinical-stage immunology biotech developing therapeutics for IMIDs (IBD, pulmonary); established strategic collaborator with IMIDomics (2020) addressing overlapping indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

IMIDomics social profiles

Digital presence

IMIDomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IMIDomics leadership team

Management profile

Number of profiles

Profiles10 records

IMIDomics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IMIDomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMIDomics

What does IMIDomics do?

IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, lupus, ulcerative colitis, psoriasis, Crohn's disease, and atopic dermatitis. Its proprietary Clinical Discovery Engine combines patient-centric clinical data from over 17,000 IMID patients, multi-omics analyses, and bioinformatics to identify novel drug targets and patient stratification biomarkers. The company partners with pharmaceutical companies (UCB, Bristol Myers Squibb, Evotec) for co-development, licensing, and commercialization of its therapeutic pipeline, including the lead program IMB1001 (anti-CD226 antibody).

Is IMIDomics a public or private company?

IMIDomics is a private company. It is classified as corporate owned and is currently acquired.

When was IMIDomics founded?

IMIDomics was founded in 2015. It employs 11 to 50 people.

Where is IMIDomics based?

IMIDomics is headquartered in San Rafael, United States, in the North America region.

How does IMIDomics make money?

Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are research Collaborations.

Who are IMIDomics's main competitors?

Direct peers on record are Prometheus Biosciences (acquired by Merck), Morphic Holding (acquired by Eli Lilly) and AbCellera Biologics. Broad incumbents are Bristol Myers Squibb, AbbVie, UCB and Eli Lilly. Emerging players are Recursion Pharmaceuticals, Exscientia and Gossamer Bio.

Does IMIDomics have an API?

No public API is recorded for IMIDomics.

What industry is IMIDomics in?

IMIDomics's product category is Biopharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup BusinessUcb accelera sull’innovazione con acquisizioni mirate in neuroscienze e immunologiaUCB, a global biopharmaceutical company, announced a series of strategic acquisitions and partnerships aimed at accelerating innovation in neuroscience and immunology. The company acquired Neurona Therapeutics to advance nervous system regeneration treatments for drug-resistant epilepsy, and IMIDomics to leverage its comprehensive data and biobank platform enhanced by AI and machine learning. Partnerships with Candid Therapeutics and Antengene will expand UCB's scientific capabilities in T and B cell modulation to restore immunological tolerance.UCBUCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)UCB acquired IMIDomics' Patient Insight Business, gaining access to a curated human dataset in immunology. The business integrates data from over 17,000 patients and samples stored in the IMID Biobank at VHIR. Financial terms were not disclosed.VallhebronFormation Bio Licenses First-in-Class Anti-CD226 Autoimmune Program from IMIDomicsFormation Bio licensed worldwide rights to IMIDomics' first-in-class anti-CD226 monoclonal antibody, which has received IND clearance. The program will be advanced in autoimmune indications, starting with ulcerative colitis, with upfront payment and milestones. The antibody targets CD226 to suppress immune overactivation.UCBUCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseasesUCB announced a strategic equity investment in IMIDomics, Inc to support the development of novel medicines for immune-mediated inflammatory diseases. The two companies are also discussing a research collaboration to leverage their respective technologies and assets to accelerate the creation of targeted therapies and diagnostic tools. Financial details of the agreement were not disclosed.Business Wire BlogIMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory TeamIMIDomics added Dr. Eric Perakslis as Senior Vice President and Chief Technology Officer and Dr. Ramon Felciano as strategic advisor. Perakslis brings over two decades of experience in pharmaceutical R&D and digital sciences, including roles at Duke Clinical Research Institute, Datavant, Takeda, and J&J. The appointments aim to accelerate data-driven drug discovery for immune-mediated inflammatory diseases.BioSpaceIMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SEEvotec SE has made an undisclosed equity investment in biotechnology company IMIDomics, Inc., with an Evotec representative joining the IMIDomics board of directors. This strategic partnership aims to advance IMIDomics' Precision Discovery Engine for developing treatments for immune-mediated inflammatory diseases. The deal expands Evotec's EVOequity portfolio while providing IMIDomics with additional resources and expertise.BioSpaceIMIDomics, IgGenix and neuro42 Close Series A Rounds Worth MillionsThree companies announced the closing of Series A financing: IMIDomics raised $16.5 million led by DNS Capital, IgGenix raised $25 million led by Khosla Ventures and Mattias Westman, and neuro42 raised $6.5 million led by Zepp Health. IMIDomics targets immune-mediated diseases including lupus and Crohn's, IgGenix focuses on allergies, and neuro42 advances MRI and robotics for brain injury diagnosis.WebcapitalriesgoIMIDomics cierra una ronda de $16,5M a la que acuden DNS Capital, Bristol Myers, The Pritzker Organization y TAO Capital, entre otrosIMIDomics, a biotech spin-off from Vall d'Hebron, has secured $16.5 million in Series A funding from investors including DNS Capital, Bristol Myers Squibb, The Pritzker Organization, and TAO Capital. The capital will be used to advance its 'IMIDomics Precision Discovery Platform' for developing new drugs targeting immunomediated inflammatory diseases. This investment marks one of the largest recent financings for a Vall d'Hebron spin-off and highlights significant investor confidence in the company's AI-driven drug discovery approach.